Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Loic Brot is active.

Publication


Featured researches published by Loic Brot.


Nature Medicine | 2016

CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands

Bruno Lamas; Mathias L. Richard; Valentin Leducq; Hang-Phuong Pham; Marie-Laure Michel; Gregory Da Costa; Chantal Bridonneau; Sarah Jegou; Thomas W. Hoffmann; Jane M. Natividad; Loic Brot; Soraya Taleb; Aurélie Couturier-Maillard; Isabelle Nion-Larmurier; Fatiha Merabtene; Philippe Seksik; Anne Bourrier; Jacques Cosnes; Bernhard Ryffel; Laurent Beaugerie; Jean-Marie Launay; Philippe Langella; Ramnik J. Xavier; Harry Sokol

Complex interactions between the host and the gut microbiota govern intestinal homeostasis but remain poorly understood. Here we reveal a relationship between gut microbiota and caspase recruitment domain family member 9 (CARD9), a susceptibility gene for inflammatory bowel disease (IBD) that functions in the immune response against microorganisms. CARD9 promotes recovery from colitis by promoting interleukin (IL)-22 production, and Card9−/− mice are more susceptible to colitis. The microbiota is altered in Card9−/− mice, and transfer of the microbiota from Card9−/− to wild-type, germ-free recipients increases their susceptibility to colitis. The microbiota from Card9−/− mice fails to metabolize tryptophan into metabolites that act as aryl hydrocarbon receptor (AHR) ligands. Intestinal inflammation is attenuated after inoculation of mice with three Lactobacillus strains capable of metabolizing tryptophan or by treatment with an AHR agonist. Reduced production of AHR ligands is also observed in the microbiota from individuals with IBD, particularly in those with CARD9 risk alleles associated with IBD. Our findings reveal that host genes affect the composition and function of the gut microbiota, altering the production of microbial metabolites and intestinal inflammation.


The American Journal of Gastroenterology | 2017

Postoperative Complications after Ileocecal Resection in Crohn’s Disease: A Prospective Study From the REMIND Group

Mathurin Fumery; Philippe Seksik; Claire Auzolle; Nicolas Munoz-Bongrand; Jean-Marc Gornet; Gilles Boschetti; Eddy Cotte; Anthony Buisson; Anne Dubois; Benjamin Pariente; Philippe Zerbib; Najim Chafai; Carmen Stefanescu; Yves Panis; Philippe Marteau; Karine Pautrat; Charles Sabbagh; Jérôme Filippi; Marc Chevrier; Pascal Houze; Xavier Jouven; Xavier Treton; Matthieu Allez; Pierre Cattan; Mircea Chirica; Hélène Corte; Clotilde Baudry; Nelson Lourenco; My-Linh Tran-Minh; Mariane Maillet

Objectives:We sought to determine the frequency of and risk factors for early (30-day) postoperative complications after ileocecal resection in a well-characterized, prospective cohort of Crohn’s disease patients.Methods:The REMIND group performed a nationwide study in 9 French university medical centers. Clinical-, biological-, surgical-, and treatment-related data on the 3 months before surgery were collected prospectively. Patients operated on between 1 September 2010 and 30 August 2014 were included.Results:A total of 209 patients were included. The indication for ileocecal resection was stricturing disease in 109 (52%) cases, penetrating complications in 88 (42%), and medication-refractory inflammatory disease in 12 (6%). A two-stage procedure was performed in 33 (16%) patients. There were no postoperative deaths. Forty-three (21%) patients (23% of the patients with a one-stage procedure vs. 9% of those with a two-stage procedure, P=0.28) experienced a total of 54 early postoperative complications after a median time interval of 5 days (interquartile range, 4–12): intra-abdominal septic complications (n=38), extra-intestinal infections (n=10), and hemorrhage (n=6). Eighteen complications (33%) were severe (Dindo–Clavien III–IV). Reoperation was necessary in 14 (7%) patients, and secondary stomy was performed in 8 (4.5%). In a multivariate analysis, corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate (odds ratio (95% confidence interval)=2.69 (1.15–6.29); P=0.022). Neither preoperative exposure to anti-tumor necrosis factor (TNF) agents (n=93, 44%) nor trough serum anti-TNF levels were significant risk factors for postoperative complications.Conclusions:In this large, nationwide, prospective cohort, postoperative complications were observed after 21% of the ileocecal resections. Corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate. In contrast, preoperative anti-TNF therapy (regardless of the serum level or the time interval between last administration and surgery) was not associated with an elevated risk of postoperative complications.


PLOS ONE | 2018

Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota

Cecilia Landman; Jean-Pierre Grill; Jean-Maurice Mallet; Philippe Marteau; Lydie Humbert; Eric Le Balc’h; Marie-Anne Maubert; Kevin Perez; Wahiba Chaara; Loic Brot; Laurent Beaugerie; Harry Sokol; Sophie Thenet; Dominique Rainteau; Philippe Seksik; Elodie Quévrain

Background and aims N-acyl homoserine lactones (AHLs), which are autoinducer quorum-sensing molecules involved in the bacterial communication network, also interact with eukaryotic cells. Searching for these molecules in the context of inflammatory bowel disease (IBD) is appealing. The aims of our study were to look for AHL molecules in faecal samples from healthy subjects (HS) and IBD patients to correlate AHL profiles with the microbiome and investigate the effect of AHLs of interest on epithelial cells. Methods Using mass spectrometry, we characterised AHL profiles in faecal samples from HS (n = 26) and IBD patients in remission (n = 24) and in flare (n = 25) and correlated the presence of AHLs of interest with gut microbiota composition obtained by real-time qPCR and 16S sequencing. We synthesised AHLs of interest to test the inflammatory response after IL1β stimulation and paracellular permeability on Caco-2 cells. Results We observed 14 different AHLs, among which one was prominent. This AHL corresponded to 3-oxo-C12:2 and was found significantly less frequently in IBD patients in flare (16%) and in remission (37.5%) versus HS (65.4%) (p = 0.001). The presence of 3-oxo-C12:2 was associated with significantly higher counts of Firmicutes, especially Faecalbacterium prausnitzii, and lower counts of Escherichia coli. In vitro, 3-oxo-C12:2 exerted an anti-inflammatory effect on Caco-2 cells. Interestingly, although 3-oxo-C12, the well-known AHL from Pseudomonas aeruginosa, increased paracellular permeability, 3-oxo-C12:2 did not. Conclusions We identified AHLs in the human gut microbiota and discovered a new and prominent AHL, 3-oxo-C12:2, which correlates with normobiosis and exerts a protective effect on gut epithelial cells.


Hepatology Communications | 2018

Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice: Debray, EL MOURABIT, et al.

Dominique Debray; Haquima El Mourabit; Fatiha Merabtene; Loic Brot; Damien Ulveling; Y. Chrétien; Dominique Rainteau; Ivan Moszer; Dominique Wendum; Harry Sokol; C. Housset

The most typical expression of cystic fibrosis (CF)–related liver disease is a cholangiopathy that can progress to cirrhosis. We aimed to determine the potential impact of environmental and genetic factors on the development of CF‐related cholangiopathy in mice. Cystic fibrosis transmembrane conductance regulator (Cftr)−/− mice and Cftr+/+ littermates in a congenic C57BL/6J background were fed a high medium‐chain triglyceride (MCT) diet. Liver histopathology, fecal microbiota, intestinal inflammation and barrier function, bile acid homeostasis, and liver transcriptome were analyzed in 3‐month‐old males. Subsequently, MCT diet was changed for chow with polyethylene glycol (PEG) and the genetic background for a mixed C57BL/6J;129/Ola background (resulting from three backcrosses), to test their effect on phenotype. C57BL/6J Cftr−/− mice on an MCT diet developed cholangiopathy features that were associated with dysbiosis, primarily Escherichia coli enrichment, and low‐grade intestinal inflammation. Compared with Cftr+/+ littermates, they displayed increased intestinal permeability and a lack of secondary bile acids together with a low expression of ileal bile acid transporters. Dietary‐induced (chow with PEG) changes in gut microbiota composition largely prevented the development of cholangiopathy in Cftr−/− mice. Regardless of Cftr status, mice in a mixed C57BL/6J;129/Ola background developed fatty liver under an MCT diet. The Cftr−/− mice in the mixed background showed no cholangiopathy, which was not explained by a difference in gut microbiota or intestinal permeability, compared with congenic mice. Transcriptomic analysis of the liver revealed differential expression, notably of immune‐related genes, in mice of the congenic versus mixed background. In conclusion, our findings suggest that CFTR deficiency causes abnormal intestinal permeability, which, combined with diet‐induced dysbiosis and immune‐related genetic susceptibility, promotes CF‐related cholangiopathy.


Gastroenterology | 2015

Mo1814 The N- Acyl-Homoserine Lactone 3-oxo-C12, an Inter-Bacterial Signaling Molecule (Involved in Quorum Sensing), Exerts Effects on the Host: Thus Implicating Quorum Sensing in Inflammatory Bowel Disease

Cecilia Landman; Mélanie Clément; Hajar Nsiri; Elodie Quévrain; Thomas Bazin; Loic Brot; Jean-Pierre Grill; Marie-Anne Maubert; Lydie Humbert; Harry Sokol; Germain Trugnan; Dominique Rainteau; Philippe Seksik

Background Exclusive enteral nutrition (EEN) is a first-line induction therapy in pediatric Crohns disease (CD). Though unclear, the mode of action of EEN is proposed to involve changes in gut microbiome structure and function. Characterization of the microbiome in IBD has largely focused on the assessment of diversity and the identification of protective and disease-associated species. More recently, metagenomic approaches to IBD microbiome investigation have facilitated predictive mapping of microbiome function. Treatment-induced changes to microbiome function may contribute to the strong therapeutic effect of EEN. Our aims were to compare microbial community structure and functional assessments of microbial metabolic pathways in pediatric CD patients before and after induction of remission by EEN treatment. Methods Metagenomic sequences from stool samples obtained from 4 pediatric Crohns disease patients who underwent EEN treatment were obtained using MiSeq whole-metagenome sequencing. Sequences were searched against the SILVA database to obtain microbial composition profiles based on 16S ribosomal RNA genes. To obtain functional assignment, sequences were searched against 28 representative KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways. Samples collected prior to EEN treatment were compared to samples collected after 8 to 12 weeks of EEN treatment. All participants achieved clinical remission (PCDAI<10) following EEN treatment. Results Changes in CD patient microbial community structure before and after EEN were variable. However, functional profiling of CD patient microbiota before and after EEN treatment revealed a significant increase in metabolic functions related to biodegradation and metabolism of xenobiotics, such as benzoate (p<0.05). Conclusions The microbiome of CD patients is functionally altered by EEN treatment, specifically increasing metabolic potential for xenobiotic biodegradation and metabolism relative to pre-treatment. Further investigations are warranted to investigate the role of altered xenobiotics metabolism in the therapeutic modality of EEN, as well as CD etiopathogenesis.


Gastroenterology | 2015

Mo1815 A Simple Biomarker for IBD Associated Dysbiosis:The Ratio of Iso-LCA/LCA Indicates Alteration of Isomeration of Bile Acids in the Intestinal Lumen

Thomas Bazin; Cecilia Landman; Manon Charrier; Camille Hannotte; Lydie Humbert; Loic Brot; Valentin Leducq; Elodie Quévrain; Jacques Cosnes; Laurent Beaugerie; Harry Sokol; Philippe Seksik; Dominique Rainteau; Marie-Anne Maubert


Gastroenterology | 2015

Mo1736 The Effect of the Electronic Cigarette on Inflammatory Response in Intestinal Epithelial Cells

Loic Brot; Elodie Quévrain; Joëlle Masliah; Germain Trugnan; Ginette Thomas; Marie Bachelet; Philippe Seksik


Journal of Hepatology | 2014

P1268 IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE IN CFTR KNOCKOUT MICE

Dominique Debray; Loic Brot; H. El Mourabit; Véronique Barbu; Dominique Rainteau; Harry Sokol; C. Housset


Gastroenterology | 2014

Sa1757 Gut Microbiota Can Induce Autophagy in Intestinal Epithelial Cells, A Concern for Crohn's Disease

My-Linh Tran-Minh; Elodie Quévrain; Loic Brot; Jean-Pierre Grill; Ginette Thomas; Germain Trugnan; Philippe Seksik


Gastroenterology | 2013

270 Implications of Faecal Microbiota Alterations in Bile Acids Metabolism in Irritable Bowel Syndrome

Dior Marie; Heloise Delagreverie; Henri Duboc; Pauline Jouet; Benoit Coffin; Loic Brot; Lydie Humbert; Germain Trugnan; Philippe Seksik; Harry Sokol; Dominique Rainteau; Jean-Marc Sabate

Collaboration


Dive into the Loic Brot's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Harry Sokol

École Normale Supérieure

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Pierre Grill

École Normale Supérieure

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dominique Debray

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge